Codexis ($CDXS) has outlined a revenue target of $72 million to $76 million for 2026, driven by momentum in its ECO Synthesis business and expanding partnerships in the contract development and manufacturing organization (CDMO) space. The company’s Q4 2025 earnings call highlighted significant milestones in its siRNA synthesis capabilities, with multiple deals signed and a strong pipeline of potential new partnerships.
The ECO Synthesis platform, which enables the efficient and cost-effective production of complex molecules, has been a key growth driver for Codexis. The company has been investing heavily in this business, and the recent milestones achieved in siRNA synthesis demonstrate the progress being made. As a result, Codexis is well-positioned to capitalize on the growing demand for high-quality siRNA molecules, which are used in a range of applications, including gene therapy and RNA-based therapeutics.
Codexis’ CDMO partnerships have also been expanding, with the company signing multiple deals with major pharmaceutical companies, including Merck and Pfizer. These partnerships provide a stable source of revenue for Codexis and demonstrate the company’s expertise in the development and manufacturing of complex molecules. The company’s Q4 2025 earnings call also highlighted the potential for further growth in this area, with a strong pipeline of potential new partnerships.
The market reaction to Codexis’ Q4 2025 earnings call has been positive, with the company’s stock price increasing by over 5% in the aftermath of the call. This reflects the optimism among investors about the company’s growth prospects, driven by the momentum in its ECO Synthesis business and expanding CDMO partnerships. The company’s revenue target for 2026, which represents a significant increase over the prior year, also demonstrates the confidence of management in the company’s ability to execute on its growth strategy.
Here are the key metrics from Codexis’ Q4 2025 earnings call:
| Metric | Q4 2025 | 2026 Guidance |
|---|---|---|
| Revenue | $18.2 million | $72 million – $76 million |
| ECO Synthesis revenue | $10.3 million | N/A |
| CDMO revenue | $7.9 million | N/A |
Looking ahead, Codexis is well-positioned to continue its growth trajectory, driven by the momentum in its ECO Synthesis business and expanding CDMO partnerships. The company’s strong pipeline of potential new partnerships and its expertise in the development and manufacturing of complex molecules provide a solid foundation for future growth. As the demand for high-quality siRNA molecules continues to grow, Codexis is likely to be a key beneficiary, with its ECO Synthesis platform and CDMO partnerships driving revenue growth and profitability.
⚡ Why it matters: Codexis’ revenue target for 2026 and its Q4 2025 earnings call highlight the company’s growth prospects, driven by its ECO Synthesis business and CDMO partnerships. The company’s expertise in the development and manufacturing of complex molecules positions it for future growth, driven by the increasing demand for high-quality siRNA molecules.
📊 By the numbers:
Revenue target for 2026: $72 million to $76 million
Q4 2025 revenue: $18.2 million
ECO Synthesis revenue in Q4 2025: $10.3 million
CDMO revenue in Q4 2025: $7.9 million
🔗 Source: Codexis Q4 2025 earnings call transcript
